Credit Suisse Raises 2015 TAVI Estimates for Edwards Lifesciences Corp.

In a report published Tuesday, Credit Suisse analyst Bruce Nudell reiterated an Outperform rating and $150.00 price target on

. In the report, Credit Suisse noted, “We're raising our 2015 transcatheter aortic valve implant (TAVI) sales estimates to $1.06B (22% CC) from $990M (13% CC) on higher assumed US market growth & market share assumptions (guidance $1.0-1.1B & 15-25% underlying growth). We're also raising our total EW 2015 sales estimate to $2.41B (10% CC) from $2.40B (7% CC) on higher TAVI estimates partially offset by greater assumed Fx headwinds & slightly lower assumed growth in Surgical Heart Valve Therapy & Critical Care. Our updated sales estimates compare to guidance of $2.3-$2.5B (7-11% underlying) & consensus of $2.48B (7% reported). We're also raising our 2015 EPS estimate to $4.03 from $3.89 primarily on lower assumed tax rate (consistent with guidance). Our updated estimates compare with EPS guidance of $3.90-$4.10 & consensus of $3.96.” Edwards Lifesciences Corp. closed on Monday at $132.13.